Learn More
BACKGROUND The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a 30 microg is(More)
Sympathoadrenergic mechanisms may play a role in multiple sclerosis (MS). We examined catecholamine (CA) levels and production and tyrosine hydroxylase (TH) expression in peripheral blood mononuclear(More)
Interferon (IFN)-g plays a pivotal role in the pathogenesis of multiple sclerosis (MS), while IFN-h may be able to modify the clinical course of the disease, eventually also by counterbalancing(More)